Contract research organization (CRO) earnings reports have been filing in over the past few weeks – and as a group, performance was positive following concerns around slowing outsourcing trends.
Steroid API firm Gadea Pharmaceuticals helped AMRI grow revenue in the second quarter offsetting flat royalties and the impact of the closure of its site in Holywell, Wales.
Medidata has reported its strongest ever quarter and says strategic CRO partnerships and risk-based monitoring offer opportunities to penetrate more of the market.
Struggling strategic partnerships and lower conversion rates from its backlog have caused Parexel stock to bottom out slightly, though executives remain optimistic on the second half of this year.
Hospira linked its improved Q2 results to progress made in efforts to address quality problems at various manufacturing plants, but the 483s and Warning Letters are still coming.
Canadian lab services contractor Warnex posted improved results for Q1 with gains made by its bioanalytical unit offsetting a decline in its analytical services business.
Pharmaceutical intermediate sales helped Codexis in Q1 but the US biocatalysis specialist still posted a net loss for the quarter on higher R&D spending
eClinical company etrials saw losses increase in the fourth quarter of 2008, but pointed to a healthy increase in orders as evidence of the underlying strength of the business.
Gerresheimer’s decision to concentrate on the pharmaceutical and life science sectors and sell-off non-core divisions appears to be paying dividends judging by a 14 per cent jump in third quarter operating profit.
Albany Molecular Research (AMRI) has slipped again in the fourth
quarter of 2006 recording an operating loss of $2.5m (€1.9m) - six
per cent worse than the same quarter the previous year - despite
encouraging revenue growth in its...
